0 52

Cited 3 times in

Adding Ovarian Suppression to Tamoxifen for Premenopausal Breast Cancer: A Randomized Phase III Trial

DC FieldValueLanguage
dc.contributor.author박병우-
dc.contributor.author정준-
dc.contributor.author정준-
dc.date.accessioned2020-04-13T17:03:20Z-
dc.date.available2020-04-13T17:03:20Z-
dc.date.issued2020-
dc.identifier.issn0732-183X-
dc.identifier.urihttps://ir.ymlib.yonsei.ac.kr/handle/22282913/175627-
dc.description.abstractPURPOSE: The addition of ovarian function suppression (OFS) for 5 years to tamoxifen (TAM) for treatment of premenopausal patients with breast cancer after completion of chemotherapy has beneficial effects on disease-free survival (DFS). This study evaluated the efficacy of adding 2 years of OFS to TAM in patients with hormone receptor-positive breast cancer who remain in a premenopausal state or resume ovarian function after chemotherapy. PATIENTS AND METHODS: We enrolled 1,483 premenopausal women (age ≤ 45 years) with estrogen receptor-positive breast cancer treated with definitive surgery after completing adjuvant or neoadjuvant chemotherapy. Ovarian function was assessed every 6 months for 2 years since enrollment on the basis of follicular-stimulating hormone levels and vaginal bleeding history. If ovarian function was confirmed to be premenopausal at each visit, the patient was randomly assigned to complete 5 years of TAM alone (TAM-only) group or 5 years of TAM with OFS for 2 years that involved monthly goserelin administration (TAM + OFS) group. DFS was defined from the time of enrollment to the time of the first event. RESULTS: A total of 1,293 patients were randomly assigned, and 1,282 patients were eligible for analysis. The estimated 5-year DFS rate was 91.1% in the TAM + OFS group and 87.5% in the TAM-only group (hazard ratio, 0.69; 95% CI, 0.48 to 0.97; P = .033). The estimated 5-year overall survival rate was 99.4% in the TAM + OFS group and 97.8% in the TAM-only group (hazard ratio, 0.31; 95% CI, 0.10 to 0.94; P = .029). CONCLUSION: The addition of 2 years of OFS to TAM significantly improved DFS compared with TAM alone in patients who remained premenopausal or resumed ovarian function after chemotherapy.-
dc.description.statementOfResponsibilityrestriction-
dc.languageEnglish-
dc.publisherAmerican Society of Clinical Oncology-
dc.relation.isPartOfJOURNAL OF CLINICAL ONCOLOGY-
dc.rightsCC BY-NC-ND 2.0 KR-
dc.titleAdding Ovarian Suppression to Tamoxifen for Premenopausal Breast Cancer: A Randomized Phase III Trial-
dc.typeArticle-
dc.contributor.collegeCollege of Medicine (의과대학)-
dc.contributor.departmentDept. of Surgery (외과학교실)-
dc.contributor.googleauthorHyun-Ah Kim-
dc.contributor.googleauthorJong Won Lee-
dc.contributor.googleauthorSeok Jin Nam-
dc.contributor.googleauthorByeong-Woo Park-
dc.contributor.googleauthorSeock-Ah Im-
dc.contributor.googleauthorEun Sook Lee-
dc.contributor.googleauthorYong Sik Jung-
dc.contributor.googleauthorJung Han Yoon-
dc.contributor.googleauthorSung Soo Kang-
dc.contributor.googleauthorSoo-Jung Lee-
dc.contributor.googleauthorKyong Hwa Park-
dc.contributor.googleauthorJoon Jeong-
dc.contributor.googleauthorSe-Heon Cho-
dc.contributor.googleauthorSung Yong Kim-
dc.contributor.googleauthorLee Su Kim-
dc.contributor.googleauthorByung-In Moon-
dc.contributor.googleauthorMin Hyuk Lee-
dc.contributor.googleauthorTae Hyun Kim-
dc.contributor.googleauthorChanheun Park-
dc.contributor.googleauthorSung Hoo Jung-
dc.contributor.googleauthorGeumhee Gwak-
dc.contributor.googleauthorJeryong Kim-
dc.contributor.googleauthorSun Hee Kang-
dc.contributor.googleauthorYoung Woo Jin-
dc.contributor.googleauthorHee Jeong Kim-
dc.contributor.googleauthorSe-Hwan Han-
dc.contributor.googleauthorWonshik Han-
dc.contributor.googleauthorMin Hee Hur-
dc.contributor.googleauthorWoo Chul Noh-
dc.contributor.googleauthorKorean Breast Cancer Study Group-
dc.identifier.doi10.1200/JCO.19.00126-
dc.contributor.localIdA01475-
dc.contributor.localIdA03727-
dc.contributor.localIdA03727-
dc.contributor.localIdA03727-
dc.contributor.localIdA03727-
dc.relation.journalcodeJ01331-
dc.identifier.eissn1527-7755-
dc.identifier.pmid31518174-
dc.identifier.urlhttps://ascopubs.org/doi/full/10.1200/JCO.19.00126-
dc.contributor.alternativeNamePark, Byeong Woo-
dc.contributor.affiliatedAuthor박병우-
dc.contributor.affiliatedAuthor정준-
dc.contributor.affiliatedAuthor정준-
dc.contributor.affiliatedAuthor정준-
dc.contributor.affiliatedAuthor정준-
dc.citation.volume38-
dc.citation.number5-
dc.citation.startPage434-
dc.citation.endPage443-
dc.identifier.bibliographicCitationJOURNAL OF CLINICAL ONCOLOGY, Vol.38(5) : 434-443, 2020-
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Surgery (외과학교실) > 1. Journal Papers

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.